<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312704</article-id>
      <article-id pub-id-type="pmc">4540538</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153750</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Azathioprine-induced accelerated cutaneous and pulmonary nodulosis in a
patient with rheumatoid arthritis<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kellet</surname>
            <given-names>Cristian Vera</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Navarrete</surname>
            <given-names>Romina Andino</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bombardieri</surname>
            <given-names>Sergio Gonz&#xE1;lez</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manriquez</surname>
            <given-names>Juan</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <aff id="aff01"><label>1</label>Pontificia Universidad Catolica de Chile - Santiago,
Chile.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Juan Manriquez, 4686 Vicu&#xF1;a Mackenna St. Santiago,
Chile. E-mail: <email>jjmanriq@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>162</fpage>
      <lpage>164</lpage>
      <history>
        <date date-type="received">
          <day>05</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We report the case of a 42-year-old female with a 5-year history of rheumatoid
arthritis treated with Rituximab and Azathioprine. Three months after the initiation
of Azathioprine, the patient started with dry cough and noted the rapid development
of multiple subcutaneous nodules on her right leg. CT scan of the chest demonstrates
pulmonary nodulosis. Skin biopsy was compatible with rheumatoid nodule. A diagnosis
of "accelerated cutaneous and pulmonary nodulosis" was considered. Azathioprine was
discontinued and Rituximab was restarted. Two months later, most of the subcutaneous
nodules had disappeared. This is the second case report of accelerated rheumatoid
nodulosis in association with Azathioprine treatment.</p>
      </abstract>
      <kwd-group>
        <kwd>Arthritis</kwd>
        <kwd>rheumatoid</kwd>
        <kwd>Azathioprine</kwd>
        <kwd>Rheumatoid nodule</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Rheumatoid arthritis (RA) is an immune-mediated disease involving chronic inflammation
and joint destruction. The skin is the most common extra-articular target of
RA.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Subcutaneous nodules are
common and occur as classic rheumatoid nodules, accelerated rheumatoid nodulosis, mainly
by methotrexate (MTX), or rheumatoid nodulosis.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Accelerated rheumatoid nodulosis has been reported only once in
association with azathioprine therapy.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>We report the case of a patient with RA treated with azathioprine who subsequently
developed accelerated cutaneous and pulmonary nodulosis.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 42-year-old-female with a 5-year history of arthritis of the fingers, swollen hand
joints and positive testing for rheumatoid factor. Nodules on the hands and other parts
of the body were not observed. She was treated with different disease-modifying
antirrheumatic drugs (initially MTX was given, then infliximab, and both were
accompanied by at least 5 mg of prednisone daily) with limited efficacy and development
of episcleritis. Treatment with rituximab and azathioprine was started in 2011 with
complete clinical response.</p>
      <p>Three months after the initiation of azathioprine, with RA in remission, the patient
started with cough without other respiratory symptoms and noted the rapid development of
multiple small subcutaneous nodules on her right leg (<xref ref-type="fig" rid="f01">Figure 1</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Multiple subcutaneous nodules on the right leg of a patient after treatment with
Azathioprine</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0162-g01"/>
      </fig>
      <p>The patient was a non-smoker and routine pre-treatment screening involved a chest
radiograph (normal) and a PPD test (negative). CT scan of the chest demonstrates
pulmonary nodulosis (<xref ref-type="fig" rid="f02">Figure 2</xref>).
QuantiFERON<sup>&#xAE;</sup>-TB was conclusively negative.</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>High-resolution CT image through the lower lung zone demonstrates peripheral
nodule</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0162-g02"/>
      </fig>
      <p>A diagnosis of "accelerated cutaneous and pulmonary nodulosis" was considered. Biopsy of
the subcutaneous nodule revealed a necrotizing area surrounded by a palisade of
histiocytes and chronic inflammatory cells compatible with rheumatoid nodule (<xref ref-type="fig" rid="f03">Figures 3</xref> and <xref ref-type="fig" rid="f04">4</xref>).</p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Microphotograph showing a rheumatoid granuloma with fibrinoid necrosis surrounded
by lymphocytes and epithelioid cells in a palisade arrangement, and vasculitis of
a hypodermic vein (HE: 200X)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0162-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Microphotograph showing a rheumatoid granuloma with fibrinoid necrosis surrounded
by lymphocytes and epithelioid cells in a palisade arrangement, and vasculitis of
a hypodermic vein (HE: 400X)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0162-g04"/>
      </fig>
      <p>Azathioprine was discontinued and Rituximab was restarted. Two months later, most of the
subcutaneous nodules had disappeared.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Accelerated rheumatoid nodulosis was first noted in 1986 by Kremer and Lee during a
study of long term MTX therapy for RA.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Since then, others have observed the same phenomenon in 8%-11% of
MTX-treated RA patients.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>This condition may develop despite improvement of arthritic symptoms and it regresses
when methotrexate is reduced or withdrawn<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. The mean time period from commencement of MTX therapy to the onset
of subcutaneous nodulosis is nearly 3 years.<sup><xref rid="r04" ref-type="bibr">4</xref></sup> HLA-DRB1*0401 and rheumatoid factor seropositivity have been
associated with MTX-induced nodulosis.<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>Accelerated rheumatoid nodulosis has also been reported in patients treated with
etanercept and leflunomide and only once in association with azathioprine
treatment.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>The nodules affect mainly the hands (metacarpophalangeal and proximal interphalangeal
joints) and other areas prone to chronic repetitive irritation, although they can occur
in a variety of sites, including the larynx, heart, lungs, sclera, tendons, synovium,
bones, peritoneum, central nervous system, and vertebral bodies. <sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>Clinically, they are subcutaneous skin-colored nodules and vary in consistency from a
firm rubbery texture to an amorphous and mobile mass. They range in size from
millimeters to several centimeters.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>The nodules are histologically identical to non-MTX-induced rheumatoid nodules. They
have three zones: an inner central necrotic zone, a second zone composed of palisading
macrophages and an outer layer of perivascular granulation tissue with chronic
inflammatory cells.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>The pathogenesis of accelerated nodulosis is still unknown, although one study
identified an adenosine-a1-receptor-mediated pathway involved in MTX-induced nodulosis.
This manifestation has never been observed in cancer patients treated with methotrexate,
suggesting that the pathogenetic mechanisms of RA are of special importance. <sup><xref rid="r01" ref-type="bibr">1</xref></sup> A recent publication reports a case of
MTX-induced accelerated rheumatoid nodulosis with MTX-associated lymphoproliferative
disorder (LPD) where Epstein-Barr virus (EBV) was detected in rheumatoid nodules and
lymph nodes. The authors propose that the improvement with the cessation of MTX suggests
that MTX-associated immunosuppression can impair immune surveillance of EBV-infected
cells; leading to the development of EBV-associated MTX-induced accelerated rheumatoid
nodulosis, as well as MTX-LPD.<sup><xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>There is no effective treatment for accelerated rheumatoid nodulosis. The principal
option is discontinuance of the causal drug. In our patient, azathioprine suspension and
Rituximab restart was effective.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>We report the case of a patient with RA treated with azathioprine, who subsequently
developed accelerated cutaneous and pulmonary nodulosis. Early diagnosis and rapid
discontinuation of the drug were critical for the successful evolution of this case.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Vera-Kellet C, Andino-Navarrete R, Gonzalez S,
Manriquez J. Azathioprine-induced accelerated cutaneous and pulmonary nodulosis in a
patient with rheumatoid arthritis. An Bras Dermatol. 2015;90 (3 Suppl 1):162-4.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study conducted at the Department of Dermatology, Pontificia Universidad Cat&#xF3;lica de
Chile. -Santiago, Chile.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prete</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Racanelli</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Digiglio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vacca</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dammacco</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Perosa</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Extra-articular manifestations of rheumatoid arthritis: An
update</article-title>
          <source>Autoimmun Rev</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>123</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="pmid">21939785</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sayah</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>English 3rd</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Rheumatoid arthritis: a review of the cutaneous
manifestations</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2005</year>
          <volume>53</volume>
          <fpage>191</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="pmid">16021111</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langevitz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maguire</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Urowitz</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Accelerated nodulosis during azathioprine therapy</article-title>
          <source>Arthritis Rheum</source>
          <year>1991</year>
          <volume>34</volume>
          <fpage>123</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">1984770</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous manifestations associated with rheumatoid
arthritis</article-title>
          <source>Rheumatol Int</source>
          <year>2009</year>
          <volume>29</volume>
          <fpage>979</fpage>
          <lpage>988</lpage>
          <pub-id pub-id-type="pmid">19242695</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Rheumatoid arthritis in dermatology</article-title>
          <source>Clin Dermatol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>430</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="pmid">16966022</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Motegi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate-induced Accelerated Nodulosis in a Patient with
Rheumatoid Arthritis and Scleroderma</article-title>
          <source>Acta Derm Venereol</source>
          <year>2014</year>
          <volume>94</volume>
          <fpage>357</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">24158350</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimoura</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fukunaga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Oka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nishigori</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Epstein-Barr Virus-associated Methotrexate-induced Accelerated
Rheumatoid Nodulosis</article-title>
          <source>Acta Derm Venereol</source>
          <year>2015</year>
          <volume>95</volume>
          <fpage>100</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="pmid">24710629</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
